|
gptkbp:instanceOf
|
antipsychotic medication
prodrug
|
|
gptkbp:activeIngredient
|
gptkb:aripiprazole
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N05AX12
|
|
gptkbp:brand
|
gptkb:Aristada
|
|
gptkbp:CASNumber
|
1257297-69-8
|
|
gptkbp:chemicalFormula
|
C36H51Cl2N5O4
|
|
gptkbp:developer
|
gptkb:Alkermes
|
|
gptkbp:drugClass
|
antipsychotic medication
|
|
gptkbp:eliminationHalfLife
|
29.2 to 34.9 days
|
|
gptkbp:form
|
extended-release injectable suspension
|
|
gptkbp:frequency
|
monthly
every 6 weeks
every 2 months
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
aripiprazole lauroxil
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
serotonin 5-HT2A receptor antagonist
serotonin 5-HT1A receptor partial agonist
dopamine D2 receptor partial agonist
|
|
gptkbp:metabolism
|
gptkb:aripiprazole
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:prodrugOf
|
gptkb:aripiprazole
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
nausea
anxiety
weight gain
insomnia
akathisia
|
|
gptkbp:usedFor
|
schizophrenia
|
|
gptkbp:bfsParent
|
gptkb:Aristada
gptkb:Abilify_Maintena
|
|
gptkbp:bfsLayer
|
8
|